| OSI Pharma is recently down 23c to $34.01. OSI Pharmaceuticals announced that the Oncologic Drugs Advisory Committee will review the use of Tarceva as a first-line maintenance therapy for patients with advanced non-small cell lung cancer who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16, 2009 meeting. Call option volume of 4,123 contracts compares to put volume of 2,560 contracts. December option implied volatility is at 45, January is at 42; near its 26-week average of 44 according to Track Data suggesting non-directional price movement. :theflyonthewall.com |
Subscribe for More Information